Published in Blood Coagul Fibrinolysis on April 01, 1993
Genetic background analysis of protein C deficiency demonstrates a recurrent mutation associated with venous thrombosis in Chinese population. PLoS One (2012) 0.92
Fulminant meningococcal septic shock in a boy with combined inherited properdin and protein C deficiency. Clin Exp Immunol (1995) 0.77
A delayed presentation of homozygous protein C deficiency in a series of children: a report on two molecular defects. Clin Case Rep (2017) 0.75
Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature (1994) 9.06
Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet (1994) 5.58
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet (1994) 5.45
Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med (1996) 4.11
Regulation of myc gene expression in HL-60 leukaemia cells by a vitamin D metabolite. Nature (1984) 3.06
Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost (2006) 3.03
High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) Blood (1995) 2.96
Genetic fingerprinting in mouthwashes of patients after allogeneic bone marrow transplantation. Bone Marrow Transplant (1999) 2.53
Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther (2001) 2.51
High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med (2000) 2.39
Atomic force microscopy: a novel approach to the detection of nanosized blood microparticles. J Thromb Haemost (2009) 2.33
Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation (1998) 2.26
Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood (1997) 2.15
High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost (2000) 2.15
Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study) Blood (1995) 2.09
Regression of colonic low grade B cell lymphoma of the mucosa associated lymphoid tissue type after eradication of Helicobacter pylori. Gut (2000) 2.08
Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost (1996) 2.07
Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost (1999) 2.04
Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med (1983) 2.03
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. Cancer Res (2001) 1.98
The putative factor IX gene promoter in hemophilia B Leyden. Blood (1988) 1.98
Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet (1993) 1.96
HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut (1999) 1.94
Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology (2004) 1.87
von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost (2006) 1.84
Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer (1985) 1.74
Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost (1998) 1.71
Alternative end-joining in follicular lymphomas' t(14;18) translocation. Leukemia (2002) 1.71
Follicular lymphomas' BCL-2/IgH junctions contain templated nucleotide insertions: novel insights into the mechanism of t(14;18) translocation. Blood (2000) 1.70
Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem (2001) 1.69
Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk. J Thromb Haemost (2007) 1.68
Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events? Stroke (2004) 1.66
Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats. Calcif Tissue Int (1980) 1.65
Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A) Stroke (1998) 1.63
High levels of factor IX increase the risk of venous thrombosis. Blood (2000) 1.61
Nucleotide sequence of a cDNA for a member of the human 90-kDa heat-shock protein family. Gene (1987) 1.60
Cerebral haemorrhagic infarction in young patients with hereditary protein C deficiency: evidence for "spontaneous" cerebral venous thrombosis. Br Med J (Clin Res Ed) (1985) 1.58
Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb Haemost (1996) 1.58
Requirement of residual thymus to restore normal T-cell subsets after human allogeneic bone marrow transplantation. Transplantation (2000) 1.55
Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost (2007) 1.55
Genetics of venous thrombosis. J Thromb Haemost (2009) 1.54
Haemophilia B: database of point mutations and short additions and deletions--eighth edition. Nucleic Acids Res (1998) 1.54
Hereditary protein S deficiency: clinical manifestations. Ann Intern Med (1987) 1.53
Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes. J Thromb Haemost (2005) 1.50
Haemophilia B: database of point mutations and short additions and deletions--fourth edition, 1993. Nucleic Acids Res (1993) 1.49
Recessive inheritance of von Willebrand's disease type I. Lancet (1993) 1.47
Preparation of lyophilized partial thromboplastin time reagent composed of synthetic phospholipids: usefulness for monitoring heparin therapy. Clin Chem (1997) 1.46
Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood (2000) 1.45
Haemophilia B (sixth edition): a database of point mutations and short additions and deletions. Nucleic Acids Res (1996) 1.44
Analysis of a positional candidate gene for inflammatory bowel disease: NRAMP2. Inflamm Bowel Dis (2000) 1.44
Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms--the Leiden Thrombophilia Study (LETS). Thromb Haemost (1994) 1.41
Genetic risk factors of venous thrombosis. Hum Genet (2001) 1.40
Clinical and laboratory data in heterozygous factor V Leiden mutation positive versus negative patients with TIA and minor stroke. Stroke (1995) 1.40
Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation. Br J Haematol (1996) 1.39
Instability of repeats of the von Willebrand factor gene variable number tandem repeat sequence in intron 40. Br J Haematol (1993) 1.39
Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemost (1982) 1.37
Haemophilia B: database of point mutations and short additions and deletions--third edition, 1992. Nucleic Acids Res (1992) 1.36
Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci U S A (2009) 1.35
Inherited thrombophilia: Part 2. Thromb Haemost (1996) 1.34
Lupus anticoagulants and thrombosis. A study of 25 cases and review of the literature. Haemostasis (1985) 1.34
Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis. J Thromb Haemost (2004) 1.33
Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol (2001) 1.33
Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood (1985) 1.33
ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost (2007) 1.32
Procoagulant activity of endocardial vegetations and blood monocytes in rabbits with Streptococcus sanguis endocarditis. Thromb Haemost (1989) 1.31
Determination of plasma protein S--the protein cofactor of activated protein C. Thromb Haemost (1985) 1.31
Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost (2012) 1.29
Disruption of a binding site for hepatocyte nuclear factor 4 results in hemophilia B Leyden. Proc Natl Acad Sci U S A (1992) 1.29
Haemophilia B: database of point mutations and short additions and deletions--second edition. Nucleic Acids Res (1991) 1.29
Prevalence of protein C deficiency in the healthy population. Thromb Haemost (1995) 1.28
Inclusion body myopathy and Paget disease is linked to a novel mutation in the VCP gene. Neurology (2005) 1.28
Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood (1994) 1.27
Genetic variants associated with deep vein thrombosis: the F11 locus. J Thromb Haemost (2009) 1.24
High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia (2005) 1.24
Haemophilia B: database of point mutations and short additions and deletions, fifth edition, 1994. Nucleic Acids Res (1994) 1.21
Haemophilia B: database of point mutations and short additions and deletions. Nucleic Acids Res (1990) 1.20
Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost (2009) 1.19
The effect of some instruments for prothrombin time testing on the International Sensitivity Index (ISI) of two rabbit tissue thromboplastin reagents. Thromb Haemost (1989) 1.19
Recurrent venous thrombosis and markers of inflammation. Thromb Haemost (2000) 1.18
APD in Paget's disease of bone. Role of the mononuclear phagocyte system? Arthritis Rheum (1980) 1.18
The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood (2000) 1.18
Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol (2006) 1.18
Contribution of factor VII genotype to activated FVII levels. Differences in genotype frequencies between northern and southern European populations. Arterioscler Thromb Vasc Biol (1997) 1.17
The use of a functional and immunologic assay for plasma protein C in the study of the heterogeneity of congenital protein C deficiency. Thromb Haemost (1984) 1.17
Stimulation of monocyte tissue factor expression in an in vitro model of bacterial endocarditis. Infect Immun (1994) 1.17
The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J (1990) 1.17
Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study. European Concerted Action on Thrombosis. Thromb Haemost (1999) 1.17
Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol (1998) 1.16
Hemophilia B Leyden: a sex-linked hereditary disorder that improves after puberty. N Engl J Med (1982) 1.16
Multiplex PCR for rapid detection of T-cell receptor-gamma chain gene rearrangements in patients with lymphoproliferative diseases. Br J Haematol (1996) 1.15
Tetranucleotide repeat polymorphism in the vWF gene. Nucleic Acids Res (1990) 1.14